To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Eicosapentaenoic and docosahexaenoic acid supplementation in breast cancer patients

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
May 2014

Eicosapentaenoic and docosahexaenoic acid supplementation in breast cancer patients

Vol: 3| Issue: 5| Number:17| ISSN#: 2564-2537
Study Type:Randomized Trial
OE Level Evidence:1
Journal Level of Evidence:N/A

High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study

Nutr Cancer. 2014;66(1):68-76. doi: 10.1080/01635581.2014.847964. Epub 2013 Nov 25

Contributing Authors:
HL Hutchins-Wiese K Picho BA Watkins Y Li S Tannenbaum K Claffey AM Kenny

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

38 postmenopausal women being treated with aromatase inhibitors for breast cancer were randomized in this trial to determine the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on bone turnover and resorption. Participants were treated with capsules of either EPA+DHA or placebo (7 capsules/day) for 3 months, after which they were analyzed for serum fatty acid composition, biom...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.

Continue